HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

Dana Horakova; Robert Zivadinov; Bianca Weinstock-Guttman; Eva Havrdova; Miriam Tamaño-Blanco; Michaela Tyblova; Sara Hussein; Niels Bergsland; Laura Willis; Jan Krasensky; Manuela Vaneckova; Zdenek Seidl; Petra Lelkova; Murali Ramanathan

doi:10.1016/j.jneuroim.2011.04.011

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

Dana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, Eva Havrdova, Miriam Tamaño-Blanco, Michaela Tyblova, Sara Hussein, Niels Bergsland, Laura Willis, Jan Krasensky, Manuela Vaneckova, Zdenek Seidl, Petra Lelkova, Murali Ramanathan

Fondazione Don Carlo Gnocchi Onlus

Research output: Contribution to journal › Article

Abstract

Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p

Original language	English
Pages (from-to)	76-80
Number of pages	5
Journal	Journal of Neuroimmunology
Volume	236
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2011.04.011
Publication status	Published - Jul 2011

Keywords

Clinically isolated syndromes
Genetics
HLA
MRI
Multiple sclerosis
Progression

ASJC Scopus subject areas

Immunology
Clinical Neurology
Immunology and Allergy
Neurology

Access to Document

10.1016/j.jneuroim.2011.04.011

Fingerprint Dive into the research topics of 'HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event'. Together they form a unique fingerprint.

Cite this

Horakova, D., Zivadinov, R., Weinstock-Guttman, B., Havrdova, E., Tamaño-Blanco, M., Tyblova, M., Hussein, S., Bergsland, N., Willis, L., Krasensky, J., Vaneckova, M., Seidl, Z., Lelkova, P., & Ramanathan, M. (2011). HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 236(1-2), 76-80. https://doi.org/10.1016/j.jneuroim.2011.04.011

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. / Horakova, Dana; Zivadinov, Robert; Weinstock-Guttman, Bianca; Havrdova, Eva; Tamaño-Blanco, Miriam; Tyblova, Michaela; Hussein, Sara; Bergsland, Niels; Willis, Laura; Krasensky, Jan; Vaneckova, Manuela; Seidl, Zdenek; Lelkova, Petra; Ramanathan, Murali.

In: Journal of Neuroimmunology, Vol. 236, No. 1-2, 07.2011, p. 76-80.

Research output: Contribution to journal › Article

Horakova, D, Zivadinov, R, Weinstock-Guttman, B, Havrdova, E, Tamaño-Blanco, M, Tyblova, M, Hussein, S, Bergsland, N, Willis, L, Krasensky, J, Vaneckova, M, Seidl, Z, Lelkova, P & Ramanathan, M 2011, 'HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event', Journal of Neuroimmunology, vol. 236, no. 1-2, pp. 76-80. https://doi.org/10.1016/j.jneuroim.2011.04.011

Horakova, Dana ; Zivadinov, Robert ; Weinstock-Guttman, Bianca ; Havrdova, Eva ; Tamaño-Blanco, Miriam ; Tyblova, Michaela ; Hussein, Sara ; Bergsland, Niels ; Willis, Laura ; Krasensky, Jan ; Vaneckova, Manuela ; Seidl, Zdenek ; Lelkova, Petra ; Ramanathan, Murali. / HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. In: Journal of Neuroimmunology. 2011 ; Vol. 236, No. 1-2. pp. 76-80.

@article{f413cec35e9549fd958ac6ee303e416c,

title = "HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event",

abstract = "Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p",

keywords = "Clinically isolated syndromes, Genetics, HLA, MRI, Multiple sclerosis, Progression",

author = "Dana Horakova and Robert Zivadinov and Bianca Weinstock-Guttman and Eva Havrdova and Miriam Tama{\~n}o-Blanco and Michaela Tyblova and Sara Hussein and Niels Bergsland and Laura Willis and Jan Krasensky and Manuela Vaneckova and Zdenek Seidl and Petra Lelkova and Murali Ramanathan",

year = "2011",

month = jul,

doi = "10.1016/j.jneuroim.2011.04.011",

language = "English",

volume = "236",

pages = "76--80",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier Science B.V.",

number = "1-2",

}

TY - JOUR

T1 - HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

AU - Horakova, Dana

AU - Zivadinov, Robert

AU - Weinstock-Guttman, Bianca

AU - Havrdova, Eva

AU - Tamaño-Blanco, Miriam

AU - Tyblova, Michaela

AU - Hussein, Sara

AU - Bergsland, Niels

AU - Willis, Laura

AU - Krasensky, Jan

AU - Vaneckova, Manuela

AU - Seidl, Zdenek

AU - Lelkova, Petra

AU - Ramanathan, Murali

PY - 2011/7

Y1 - 2011/7

N2 - Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p

AB - Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p

KW - Clinically isolated syndromes

KW - Genetics

KW - HLA

KW - MRI

KW - Multiple sclerosis

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=79960158179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960158179&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2011.04.011

DO - 10.1016/j.jneuroim.2011.04.011

M3 - Article

C2 - 21621859

AN - SCOPUS:79960158179

VL - 236

SP - 76

EP - 80

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -